Original Article
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Marcello Tonelli, Brenda Hemmelgarn, Tony Reiman, Braden Manns, M Neil Reaume, Anita Lloyd, Natasha Wiebe and Scott Klarenbach
CMAJ April 30, 2009 DOI: https://doi.org/10.1503/cmaj.090470
Marcello Tonelli
Brenda Hemmelgarn
Tony Reiman
Braden Manns
M Neil Reaume
Anita Lloyd
Natasha Wiebe
This is a PDF-only article.
In this issue
Article tools
Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis
Marcello Tonelli, Brenda Hemmelgarn, Tony Reiman, Braden Manns, M Neil Reaume, Anita Lloyd, Natasha Wiebe, Scott Klarenbach
CMAJ Apr 2009, DOI: 10.1503/cmaj.090470
Jump to section
Related Articles
Cited By...
- A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
- Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-like Cells to Protect Them from Chemotherapy
- Cancer- and Chemotherapy-Induced Anemia
- Effects of Funding Policy Changes and Health Warnings on the Use of Erythropoiesis-Stimulating Agents
- Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes
- The Role of Erythropoietin and Erythropoiesis-Stimulating Agents in Tumor Progression
- Recombinant Human Erythropoietin in Combination with Chemotherapy Increases Breast Cancer Metastasis in Preclinical Mouse Models
- Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study
- American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer
- American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer
- Hemoglobin and Aerobic Fitness Changes with Supervised Exercise Training in Breast Cancer Patients Receiving Chemotherapy
- 2009: A Requiem for rHuEPOs--But Should We Nail Down the Coffin in 2010?
- Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
- Concern About Erythropoiesis-Stimulating Agents for Cancer Patients
- Introduction to surrogates and evidence-based mini-reviews